Nonadditivity in public and inhouse data: implications for drug design

D. Gogishvili, E. Nittinger^*, C. Margreitter, C. Tyrchan

^*Corresponding author for this work

Research output: Contribution to Journal › Article › Academic › peer-review

Additional file 4 of Nonadditivity in public and inhouse data: implications for drug design
Tyrchan, C. (Contributor), Margreitter, C. (Contributor), Gogishvili, D. (Contributor) & Nittinger, E. (Contributor), figshare Academic Research System, 1 Jan 2021
DOI: 10.6084/m9.figshare.14904132.v1, https://doi.org/null
Dataset / Software: Dataset
Additional file 2 of Nonadditivity in public and inhouse data: implications for drug design
Nittinger, E. (Contributor), Tyrchan, C. (Contributor), Gogishvili, D. (Contributor) & Margreitter, C. (Contributor), figshare Academic Research System, 1 Jan 2021
DOI: 10.6084/m9.figshare.14904126.v1, https://doi.org/null
Dataset / Software: Dataset
Additional file 3 of Nonadditivity in public and inhouse data: implications for drug design
Nittinger, E. (Contributor), Margreitter, C. (Contributor), Gogishvili, D. (Contributor) & Tyrchan, C. (Contributor), figshare Academic Research System, 1 Jan 2021
DOI: 10.6084/m9.figshare.14904129.v1, https://doi.org/null
Dataset / Software: Dataset

Datasets